Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG:2196)

HKG:2196 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	38,877	40,396	40,911	43,377	38,666	29,910
Other Revenue	671.23	671.23	488.71	574.48	345.58	396.96
Revenue	39,549	41,067	41,400	43,952	39,011	30,307
Revenue Growth (YoY)	-4.96%	-0.80%	-5.81%	12.66%	28.72%	6.02%
Cost of Revenue	20,762	21,426	21,717	23,256	20,294	13,798
Gross Profit	18,787	19,641	19,683	20,696	18,717	16,509
Selling, General & Admin	12,563	12,963	14,087	12,999	12,328	11,124
Research & Development	3,726	3,644	4,346	4,302	3,837	2,795
Other Operating Expenses	-58.91	-47.52	-44.99	-88.15	-57.86	-108.24
Operating Expenses	16,330	16,668	18,499	17,275	16,180	13,891
Operating Income	2,457	2,974	1,184	3,420	2,537	2,618
Interest Expense	-1,338	-1,432	-1,325	-963.81	-822.54	-880.95
Interest & Investment Income	4,031	2,478	3,866	4,660	4,858	2,484
Currency Exchange Gain (Loss)	-13.36	-13.36	13.03	62.36	154.63	-24.79
Other Non Operating Income (Expenses)	-84.78	-41.41	-57.73	-31.78	-31.06	-81.16
EBT Excluding Unusual Items	5,052	3,965	3,680	7,147	6,695	4,115
Impairment of Goodwill	-	-	-	-180	-150	-
Gain (Loss) on Sale of Investments	-384.8	-115.94	-488.66	-2,498	-110.19	494.8
Gain (Loss) on Sale of Assets	431.26	371.01	5.56	125.6	-15.42	5.71
Asset Writedown	-101.31	-57.93	-42.14	-20.48	-171.01	-10.11
Other Unusual Items	-74.86	-5.44	109.38	0.25	-206.16	72.71
Pretax Income	4,935	4,169	3,265	4,574	6,043	4,678
Income Tax Expense	885.04	656.84	369.5	626.92	1,066	737.86
Earnings From Continuing Operations	4,050	3,512	2,895	3,947	4,976	3,940
Minority Interest in Earnings	-767.48	-742.55	-508.8	-216.66	-247.56	-277.17
Net Income	3,283	2,770	2,386	3,731	4,729	3,663
Preferred Dividends & Other Adjustments	-	-	1.05	-	-	-
Net Income to Common	3,283	2,770	2,385	3,731	4,729	3,663
Net Income Growth	55.29%	16.08%	-36.04%	-21.10%	29.10%	10.27%
Shares Outstanding (Basic)	2,652	2,670	2,670	2,607	2,563	2,563
Shares Outstanding (Diluted)	2,652	2,670	2,670	2,607	2,563	2,563
Shares Change (YoY)	-1.39%	0.02%	2.40%	1.74%	-	-
EPS (Basic)	1.24	1.04	0.89	1.43	1.85	1.43
EPS (Diluted)	1.24	1.04	0.89	1.43	1.85	1.43
EPS Growth	57.56%	16.10%	-37.52%	-22.50%	29.10%	10.27%
Free Cash Flow	320.33	66.79	-1,922	-1,671	-1,035	-1,857
Free Cash Flow Per Share	0.12	0.03	-0.72	-0.64	-0.40	-0.72
Dividend Per Share	0.320	0.320	0.270	0.420	0.560	0.430
Dividend Growth	18.52%	18.52%	-35.71%	-25.00%	30.23%	10.26%
Gross Margin	47.50%	47.83%	47.54%	47.09%	47.98%	54.47%
Operating Margin	6.21%	7.24%	2.86%	7.78%	6.50%	8.64%
Profit Margin	8.30%	6.74%	5.76%	8.49%	12.12%	12.09%
Free Cash Flow Margin	0.81%	0.16%	-4.64%	-3.80%	-2.65%	-6.13%
EBITDA	4,878	5,514	3,883	5,541	4,184	4,083
EBITDA Margin	12.33%	13.43%	9.38%	12.61%	10.72%	13.47%
D&A For EBITDA	2,421	2,540	2,699	2,121	1,647	1,465
EBIT	2,457	2,974	1,184	3,420	2,537	2,618
EBIT Margin	6.21%	7.24%	2.86%	7.78%	6.50%	8.64%
Effective Tax Rate	17.93%	15.75%	11.32%	13.71%	17.65%	15.77%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.